Insights

  • Date

  • Content Type

  • Reset

Blog

Continuous Progress in Continuous Manufacturing

3.06.19

By David Koziel

As manufacturers of biopharmaceuticals face growing challenges in the development and commercialization of products, advanced technologies, e.g....

Read More

Blog

EMA’s Article 58 procedure and WHO’s prequalification procedure – pathways to licensure worth to consider for vaccines and other medicinal products

18.04.19

By Michael Pfleiderer

There are challenges and opportunities for developers of vaccines and other medicinal products needed outside the EU...

Read More

Blog

Five tips to streamline paediatric investigation plan (PIP) preparation

2.04.19

By Linsey Reavie

In order to receive approval for a marketing authorisation application (MAA) in the European Union, Sponsors must...

Read More

Blog

Newly approved second generation of CDK4/6 inhibitors give hope to breast cancer patients

20.03.19

By Ilona Baraniak

Breast cancer is the most common type of cancer in women worldwide, with nearly 1.3 million new...

Read More

Blog

Harnessing the power of the immune system: from bispecific antibodies to CAR-Ts and beyond

25.02.19

By Diane Seimetz

The first class of therapeutic products harnessing the power of T cells for target-specific treatment of oncological diseases...

Read More

Blog

Let’s Celebrate! – Success Stories from Biopharma Excellence 🍾

15.02.19

By Biopharma Excellence

Already in the beginning of 2019, the Biopharma Excellence has several good reasons to celebrate.
Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more